Edwards Lifesciences (EW) Earnings Analysis

Edwards Lifesciences (EW) next reports earnings on 2026-07-23, consensus EPS 0.743 USD. Last quarter (2026-04-23) it beat with EPS 0.78 USD vs 0.729 USD est (+7%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E 44.64.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does EW next report earnings?

Next earnings date2026-07-23
Consensus EPS estimate0.743 USD
Revenue estimate1.70B

EW earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-230.78 USD0.729 USD+7%Beat
2025-10-300.67 USD0.596 USD+12.4%Beat
2025-07-240.67 USD0.624 USD+7.4%Beat
2024-10-240.67 USD0.665 USD+0.8%Beat
2024-07-240.7 USD0.69 USD+1.4%Beat

Beat rate: 5/5 (100%) over reported quarters with consensus data.

EW valuation and analyst view

Trailing P/E44.64
Trailing EPS1.887 USD
Price / book4.73
Dividend yield0.00%
Market cap48.56B
Analyst consensusBuy (32 buy / 16 hold / 0 sell)
Avg price target99.22 USD

Related research pages

Frequently asked questions

When is Edwards Lifesciences (EW)'s next earnings date?

Edwards Lifesciences is next scheduled to report on 2026-07-23, with a consensus EPS estimate of 0.743 USD and revenue estimate of 1.70B.

Did EW beat earnings last quarter?

In its 2026-04-23 report, EW posted EPS of 0.78 USD versus a 0.729 USD estimate — a beat of 7%.

What is EW's earnings track record?

Over the last 5 reported quarters with consensus data, EW beat estimates 5 times (100%).

What is EW's current P/E ratio and EPS?

EW trades at a trailing P/E of 44.64 on trailing EPS of 1.8867403314917126 USD.

What do analysts rate EW?

Analyst consensus is "Buy" across 48 ratings (0 strong buy, 32 buy, 16 hold, 0 sell, 0 strong sell). Average 12-month price target: 99.22 USD.